Rubraca
New price gets Clovis’ PARP inhibitor on the CDF
George Underwood
CDF, Clovis, Clovis Oncology, ovarian cancer, PARP inhibitor, Rubraca
0 Comment
Relief for GSK as Tesaro’s Zejula hits the mark in ovarian cancer
Phil Taylor
AstraZeneca, Clovis Oncology, Forxiga, GSK, Lynparza, Oncology, ovarian cancer, PARP inhibitor, Rubraca, type 1 diabetes, Zejula
0 Comment
Oncology/ Views & Analysis/ Views and analysis
Janssen CAR-T is Priority Medicine in EU, and more
Richard Staines
BMS-Celegene merger, CAR T, Clovis Oncology, Janssen, radiopharmaceuticals, Rubraca
0 Comment
News/ News/ Oncology/ R&D/ Roche/ Top pharmaceutical companies
Tesaro stock rockets as rumours of Roche takeover abound
Joy Persaud
cancer, Clovis Oncology, Oncology, Roche, Rubraca, Tesaro, Zejula
0 Comment